Jules Netherland traveled from her home in the Bronx to the New York state Capitol in Albany several times in the past few years, hoping to persuade the legislature to pass a medical aid in dying bill, allowing terminally ill patients to end their lives with a lethal prescription. She spoke at rallies. With other…
Health tech companies made several major funding announcements in September. Here is a list of some of the biggest funding rounds. The post 5 Notable Health Tech Funding Announcements in September appeared first on MedCity News.
Inozyme Pharma’s main asset is in pivotal testing in children who have a rare enzyme deficiency that affects bones and blood vessels. BioMarin Pharmaceutical, already well established in enzyme replacement, said it will use its experience and infrastructure to grow the market for this product, potentially for several indications. The post BioMarin’s $270M Inozyme Acquisition…
Let’s say you’re the CEO of a health plan. A new drug just received approval to treat patients with lung cancer. The drug’s clinical trial examined how well the the drug worked on third line (3L) patients and patients with good funcional ability (e.g., performance status ECOG score of 0 or 1). FDA approved the…
The next wave of radiology AI value will come from closed-loop follow-up. An actionable finding should start a pathway with a measurable end state: the follow-up exam is completed, the referral is completed, or the recommendation is clinically resolved with a documented rationale. The post The Last Mile Problem in AI Radiology: Detection Improves, Follow-Through…
UnitedHealthcare is exempting rural providers from most prior authorization requirements. The post UnitedHealthcare Expands Rural Healthcare Initiatives, Reduces Prior Auth Requirements appeared first on MedCity News.
In a recent report, the Association of the British Pharmaceutical Industry (ABPI) examines the UK’s “translational readiness gap”—the persistent failure to move cutting-edge laboratory models into the actual creation of medicines to treat patients. The Attrition Problem and the Translational Gap Modern drug development is a high risk endeavor. Approximately 90% of drug candidates that…
While data and cost are important elements in recognizing issues, the measure of success isn’t just about the data or the numbers; it’s about ensuring that older adults can manage and maintain their expectations about health and aging in place. The post Beyond the Numbers: Every Data Point Tells a Different Story appeared first on…
Every clinical encounter must be viewed as a medication reconciliation opportunity and primary care physicians are the coordinators-in-chief. The post How Care Transitions Complicate Medication Management — and How to Fix Them appeared first on MedCity News.
FDA approval of Icotyde covers the treatment of adults and adolescents with moderate-to-severe plaque psoriasis. This once-daily pill, developed by partners Johnson & Johnson and Protagonist Therapeutics, offers an easier dosing option compared to injectables and is projected to become a blockbuster seller across several immunological indications. The post J&J Gets FDA Nod for Plaque…